News New cystic fibrosis triple from Vertex backed for NHS use Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.
News ADA: Vertex closer to weaning type 1 diabetics off insulin A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.
News Italfarmaco closes on EU okay for Duchenne drug Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
News Share in cystic fibrosis firm Sionna rise sharply after IPO Sionna has closed its IPO, raising $191m for cystic fibrosis candidates that it thinks could be more effective than rivals from Vertex.
News Algiax non-opioid drug works in chronic neuropathic pain A GABA-targeting drug developed by German Biotech Algiax has shown proof of concept in a chronic neuropathic trial trial.
News GSK adds EU to Blenrep checklist as FDA sets new PDUFA date GSK has added the EMA to the list of regulatory bodies approving Blenrep for multiple myeloma, but whether the FDA is next is still an open question.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face